Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BDSX
stocks logo

BDSX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
24.84M
+21.59%
-0.942
-21.5%
23.17M
+29%
-0.760
-52.5%
25.33M
+26.55%
-0.633
-60.42%
Estimates Revision
The market is revising Upward the revenue expectations for Biodesix, Inc. (BDSX) for FY2025, with the revenue forecasts being adjusted by 1.86% over the past three months. During the same period, the stock price has changed by -3.26%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.86%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-9.66%
In Past 3 Month
Stock Price
Go Down
down Image
-3.26%
In Past 3 Month
Wall Street analysts forecast BDSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDSX is 30.00 USD with a low forecast of 20.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast BDSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDSX is 30.00 USD with a low forecast of 20.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.540
sliders
Low
20.00
Averages
30.00
High
40.00
Current: 8.540
sliders
Low
20.00
Averages
30.00
High
40.00
Canaccord
Buy
downgrade
$30 -> $20
2025-09-19
Reason
Canaccord
Price Target
$30 -> $20
2025-09-19
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Biodesix to $20 from $30 and keeps a Buy rating on the shares. The firm updated its model to reflect its 20-for-1 reverse split which reduces the amount of outstanding shares to 8 million from 156 million. Importantly, the company appears to have an at-the-market facility it could leverage to help it maintain operations through potentially cash flow breakeven/profitability.
Scotiabank
Outperform
to
NULL
downgrade
$3 -> $2
2025-05-21
Reason
Scotiabank
Price Target
$3 -> $2
2025-05-21
downgrade
Outperform
to
NULL
Reason
Scotiabank lowered the firm's price target on Biodesix to $2 from $3 and keeps an Outperform rating on the shares. The company's Q1 revenue miss and FY25 revenue guidance reduction can be attributed to the shift in the company's commercial strategy, the analyst tells investors. The firm continues to believe the market for lung nodule risk assessment is a multi-billion-dollar opportunity that is under-penetrated and the company faces minimal competition.
William Blair
William Blair
Outperform -> Market Perform
downgrade
2025-05-14
Reason
William Blair
William Blair
Price Target
2025-05-14
downgrade
Outperform -> Market Perform
Reason
Canaccord
Kyle Mikson
Buy
downgrade
2025-05-14
Reason
Canaccord
Kyle Mikson
Price Target
2025-05-14
downgrade
Buy
Reason
Canaccord analyst Kyle Mikson lowered the firm's price target on Biodesix to $1.50 from $2.50 and keeps a Buy rating on the shares. The firm said the target decrease is driven by lower near- and long-term revenue estimates after the company posted Q1 results that were below expectations.
TD Cowen
Buy
downgrade
$3 -> $2
2025-05-14
Reason
TD Cowen
Price Target
$3 -> $2
2025-05-14
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Biodesix to $2 from $3 and keeps a Buy rating on the shares. The firm updated its model as sales force issues were a drag on 1Q results and the guide down.
Craig-Hallum
Buy
downgrade
$3
2025-05-14
Reason
Craig-Hallum
Price Target
$3
2025-05-14
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on Biodesix to $1.50 from $3 and keeps a Buy rating on the shares. The firm believes Biodesix is likely to sell off even further on a Q1 volume and revenue miss and lowered guidance. The company cites disruption from a sales force reorganization. Craig-Hallum expects it will take a few quarters for the company to get back on the right track, and thus has revised its estimates below the low end of the new guidance range.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Biodesix Inc (BDSX.O) is -2.97, compared to its 5-year average forward P/E of -4.65. For a more detailed relative valuation and DCF analysis to assess Biodesix Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.65
Current PE
-2.97
Overvalued PE
-0.27
Undervalued PE
-9.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.23
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.68
Undervalued EV/EBITDA
-16.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.17
Current PS
0.00
Overvalued PS
5.91
Undervalued PS
0.43
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1991.2% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BDSX News & Events

Events Timeline

(ET)
2025-11-03
16:18:57
Biodesix increases FY25 revenue forecast to $84M-$86M, up from $80M-$85M, surpassing consensus of $83.24M.
select
2025-11-03
16:17:26
Biodesix announces Q3 earnings per share of $1.16, below consensus estimate of $1.51
select
2025-10-22 (ET)
2025-10-22
06:19:31
Biodesix broadens collaboration with Bio-Rad
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-04NASDAQ.COM
Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead

  • Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.

  • Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.

  • Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.

  • Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.

[object Object]
Preview
4.5
10-31TipRanks
Daily Update on VTI ETF for October 31, 2025

  • VTI ETF Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 1.06% over the past week and 17.62% year-to-date, despite a 1.07% decline on Thursday amid rising global tensions.

  • Investor Activity: VTI saw a net inflow of $38 million over the last five trading days, with an average trading volume of 4.08 million shares, indicating strong investor interest.

  • Analyst Consensus: VTI is rated as a Moderate Buy by analysts, with a price target of $379.46 suggesting a potential upside of 13.58%.

  • Top Holdings and Potential: The ETF's largest holdings include Nvidia, Microsoft, and Apple, while its top five stocks with the highest upside potential are FlexShopper, FibroBiologics, Biodesix, BioAtla, and Cibus.

[object Object]
Preview
4.5
10-30TipRanks
Daily Update on VTI ETF for October 30, 2025

  • VTI ETF Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 2.07% over the past five days and 17.62% year-to-date, despite a slight decline of 0.07% on Wednesday.

  • Investor Activity: VTI saw a net inflow of $38 million over the last five trading days, with an average trading volume of 4.08 million shares.

  • Analyst Consensus: VTI is rated as a Moderate Buy by analysts, with a price target of $379.46 indicating a potential upside of 12.36%.

  • Top Holdings and Potential: The ETF's top holdings include Nvidia, Microsoft, and Apple, while it has identified several stocks with high upside potential and others with significant downside risks.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Biodesix Inc (BDSX) stock price today?

The current price of BDSX is 8.54 USD — it has increased 4.91 % in the last trading day.

arrow icon

What is Biodesix Inc (BDSX)'s business?

Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.

arrow icon

What is the price predicton of BDSX Stock?

Wall Street analysts forecast BDSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDSX is 30.00 USD with a low forecast of 20.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Biodesix Inc (BDSX)'s revenue for the last quarter?

Biodesix Inc revenue for the last quarter amounts to 21.77M USD, increased 19.93 % YoY.

arrow icon

What is Biodesix Inc (BDSX)'s earnings per share (EPS) for the last quarter?

Biodesix Inc. EPS for the last quarter amounts to -1.16 USD, decreased -17.14 % YoY.

arrow icon

What changes have occurred in the market's expectations for Biodesix Inc (BDSX)'s fundamentals?

The market is revising Upward the revenue expectations for Biodesix, Inc. (BDSX) for FY2025, with the revenue forecasts being adjusted by 1.86% over the past three months. During the same period, the stock price has changed by -3.26%.
arrow icon

How many employees does Biodesix Inc (BDSX). have?

Biodesix Inc (BDSX) has 273 emplpoyees as of December 05 2025.

arrow icon

What is Biodesix Inc (BDSX) market cap?

Today BDSX has the market capitalization of 66.99M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free